<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i> -Amplified Esophagogastric CancerFrancisco Sánchez-Vega, Yelena Y. Janjigian, Richard B. Lanman et al.|Cancer Discovery|2018Cited by 147
Supplementary Tables S1-S10 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric CancerFrancisco Sánchez-Vega, Yelena Y. Janjigian, Jaclyn F. Hechtman et al.|Unknown|2023Cited by 0
Supplementary Figure Legends from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric CancerFrancisco Sánchez-Vega, Yelena Y. Janjigian, Jaclyn F. Hechtman et al.|Unknown|2023Cited by 0
Figure S1 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric CancerFrancisco Sánchez-Vega, Yelena Y. Janjigian, Jaclyn F. Hechtman et al.|Unknown|2023Cited by 0
Figure S2 from <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric CancerFrancisco Sánchez-Vega, Yelena Y. Janjigian, Jaclyn F. Hechtman et al.|Unknown|2023Cited by 0